Anticipated Financial Results from Seres Therapeutics
Seres Therapeutics, Inc. (NASDAQ: MCRB) is gearing up for an exciting announcement of its second quarter financial results. On August 6, 2025, at 8:30 a.m. ET, the company’s management will hold a conference call and live audio webcast. This will offer a detailed overview of both their financial performance and the latest updates on their business strategy.
How to Access the Conference Call
To participate in the call, investors can dial in at 800-715-9871 for domestic access or 646-307-1963 for international callers. Make sure to mention the conference ID number 3641971 when calling. Additionally, for those who prefer to follow along online, the live webcast can be accessed through the 'Investors and News' section on the Seres Therapeutics website.
Engagement Beyond the Live Event
After the live event, a replay of the webcast will be available on Seres' website approximately two hours later, allowing those who couldn't tune in live the opportunity to catch up on the important updates. The replay will remain accessible for around 21 days, ensuring that interested parties have ample time to review the discussion.
About Seres Therapeutics
Seres Therapeutics operates at the forefront of biotherapeutics, focusing on delivering improved patient outcomes for medically vulnerable populations through innovative therapies. One of their significant achievements is the development of VOWST™, which holds the distinction of being the first FDA-approved orally administered microbiome therapeutic. This groundbreaking product was sold to Nestlé Health Science. Currently, the company is advancing its promising candidate, SER-155, which has received Breakthrough Therapy designation aimed at significantly reducing bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Clinical Success and Future Developments
SER-155 is showing promise based on its Phase 1b clinical study results, demonstrating a significant decrease in bloodstream infections and related complications when compared to placebo. This candidate is not only targeted at allo-HSCT patients but is also being evaluated for efficacy in various other vulnerable groups, including autologous-HSCT patients, cancer patients suffering from neutropenia, CAR-T therapy recipients, and individuals with chronic liver conditions.
Expanding Treatment Scope with Innovative Solutions
Seres believes in the extensive potential of SER-155 and other biotherapeutic candidates, which are produced through standardized clonal cell banks, contrasting the donor-sourced methods utilized for VOWST. The company aspires to leverage its expertise to tackle multiple disease-relevant pathways and enhance therapeutic options for patients in critical care, long-term acute care facilities, and those undergoing solid organ transplants.
Investor and Media Communication
For inquiries, interested individuals can reach out via email to IR@serestherapeutics.com. This line of communication is directed by Carlo Tanzi, Ph.D., who is associated with Kendall Investor Relations. For further details, he can be contacted at ctanzi@kendallir.com.
Frequently Asked Questions
What is the purpose of the conference call on August 6?
The conference call will discuss Seres Therapeutics' second quarter financial results and provide updates on their business strategy.
How can I listen to the conference call?
Participants can join by dialing 800-715-9871 (domestic) or 646-307-1963 (international) and using the conference ID 3641971, or by accessing the live webcast on their website.
What notable product has Seres Therapeutics developed?
Seres developed VOWST™, the first FDA-approved orally administered microbiome therapeutic, enhancing patient options for microbiome-directed therapies.
What is SER-155 and its significance?
SER-155 is a candidate designed to reduce bloodstream infections in patients undergoing allo-HSCT, with significant clinical results highlighting its efficacy.
How does Seres Therapeutics aim to impact various patient populations?
They intend to evaluate SER-155 in several medically vulnerable groups, aiming to enhance treatment outcomes through innovative biotherapeutics.
